STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 101–200 of 1,004
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
“A recent report has highlighted an association of mutation in STK11 and anti-PD1 treatment failures (34).”
BackgroundThe path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
“The phase 2 trial evaluated the efficacy and safety of sotorasib monotherapy in patient with locally advanced or metastatic KRAS p.G12C-mutated NSCLC previously treated with standard therapies for KRAS-mutated NSCLC [108].”
BackgroundHong, L., Negrao, M. V., Dibaj, S. S., Chen, R., Reuben, A., Bohac, J. M., Liu, X., Skoulidis, F., Gay, C. M., Cascone, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.026 · Cited by 187
Self-citationAshrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. D. C., Deese, A. R., & Zhang, L. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 183
Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187
Self-citationImmune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Biomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 183
“Out of these three subtypes, it was found that the KL subtype was associated with reduced objective response rate and progression-free survival following anti-PD-1 treatment [50].”
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A., Negrón Abril, Y. L., Goldford, J., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 179
Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L., Xu, H., Cao, Z., Feng, X., Xue, Q., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12327 · Cited by 175
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180
“(4, 23) demonstrated that, among KRAS mutated LUAD, tumors with STK11(LKB1) mutations are immunologically “cold” and are intrinsically resistant to anti-PD1/PD-L1 immunotherapy, and they have low expression of immune markers (including PD1, CTLA4, PD-L1, CD8) compared to other LUAD.”
InfluentialSelf-citationCancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 173
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
“In addition, specific comutations, most notably involving STK11, are associated with reduced benefit from ICI as discussed previously.(60,64,190) Rare alterations in other genes, which influence the tumor immunemicroenvironment, may also be associated with primary or acquired resistance in NSCLC, and these gene altera…”
BackgroundSelf-citationImmune Escape Mechanisms in Non Small Cell Lung Cancer
Anichini, A., Perotti, V. E., Sgambelluri, F., & Mortarini, R. (2020) · Cancers · doi:10.3390/cancers12123605 · Cited by 169
“2%, respectively, in the three KRAS molecular subsets, even among patients enrolled in the CheckMate-057 phase III trial [43].”
BackgroundResultThe AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168
“treatment options are extremely limited [12-14].”
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 167
“, single-arm studies) aswell as a phase III trialwith limited numbers of KRAS-mutant, STK11-null tumors (n1⁄4 6 for anti–PD-1 and n1⁄4 3 for docetaxel arms) proposed STK11 loss to be a genomic driver of resistance to PD-1 checkpoint inhibitors in KRAS-mutant lung adenocarcinoma, suggesting it to be predictive rather t…”
BackgroundResultGenomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001282 · Cited by 165
Self-citationBinkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., Kunder, C., Stehr, H., Yoo, C. H., Rhee, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0282 · Cited by 163
“In an exploratory analysis we also examined if STK11 mutations were associated with LR after RT since these have been implicated in treatment resistance to other therapies (28,30,31).”
MethodThe improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 159
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Ren, F., Fei, Q., Qiu, K. L., Zhang, Y., Zhang, H., & Sun, L. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03026-7 · Cited by 203
“The detection of co-mutations in STK11/KRAS has been recognized as an indicator of worse survival outcomes in patients undergoing treatment with ICIs [232], reinforcing the viability of detecting mutation sites associated with immunotherapy to predict its effectiveness.”
BackgroundImmuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., & Valabrega, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124414 · Cited by 159
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 158
“[63] 2018 PD-1/PD-L1 inhibitors 1208 STK11/LKB1 2B – –”
BackgroundMechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
“For example, mutations of KEAP1 and STK11 appear to induce a colder immune microenvironment with decreased T-cell infiltration, and are associated with poor clinical outcome in NSCLC treated with frontline chemo-immunotherapy (46).”
BackgroundAlessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 155
Self-citationExploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Clinicopathologic Characteristics of BRG1-Deficient NSCLC
Dagogo‐Jack, I., Schrock, A. B., Kem, M., Jessop, N. A., Lee, J., Ali, S. M., Ross, J. S., Lennerz, J. K., Shaw, A. T., & Mino-Kenudson, M. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.002 · Cited by 165
Self-citationSivakumar, S., Moore, J. A., Montesion, M., Sharaf, R., Lin, D. I., Colón, C. I., Fleischmann, Z., Ebot, E. M., Newberg, J. Y., Mills, J. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0620 · Cited by 175
Self-citationShim, J. H., Kim, H. S., Cha, H., Kim, S., Kim, T. M., Anagnostou, V., Choi, Y.-L., Jung, H. A., Sun, J.-M., Ahn, J. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.004 · Cited by 143
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Kim, J., Lee, H. M., Cai, F., Ko, B., Yang, C., Lieu, E. L., Muhammad, N., Rhyne, S., Li, K., Haloul, M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00316-0 · Cited by 142
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Self-citationGupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 156
Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00208-6 · Cited by 140
Self-citationDantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 164
“NTRK gene fusions in NSCLC may be associated with higher TMB and PD-L1 expression than other molecularly defined subgroups [90].”
BackgroundDendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C. S., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 137
“T-cell infiltration and nonresponse to ICB therapy (40, 41), and correspondingly STING signaling pathways can be inhibited by LKB1 loss.”
BackgroundHuang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 135
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
Domblides, C., Leroy, K., Monnet, I., Mazières, J., Barlési, F., Gounant, V., Baldacci, S., Mennecier, B., Toffart, A., Audigier-Valette, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.014 · Cited by 134
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 202
Self-citationAredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 153
“Mutations in PTEN (22, 25),NRAS (11), BRAF (11), PBRM1, and other components of the polybromo-associated BRG-/BRM-associated factor (PBAF) complex (26, 27) affect antitumor responses.”
InfluentialSelf-citationVariant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 140
Guibert, N. M., Pradines, A., Favre, G., & Mazières, J. (2020) · European Respiratory Review · doi:10.1183/16000617.0052-2019 · Cited by 152
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
“Co-occurring genetic mutations, which can lead to differential downstream effectors engaged by mutant KRAS, have been reported to significantly affect the tumor immune signatures (25, 29, 31, 35) and responses to immunotherapy (30).”
BackgroundRoch, B., Coffy, A., Jean-Baptiste, S., Palaysi, E., Daurès, J., Pujol, J.-L., & Bommart, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.003 · Cited by 137
Arbour, K. C., Rizvi, H., Plodkowski, A. J., Hellmann, M. D., Knezevic, A., Heller, G., Yu, H. A., Ladanyi, M., Kris, M. G., Arcila, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4023 · Cited by 126
“While these drugs are a substantial improvement compared with other targeted therapy approaches for KRAS-mutant NSCLC (6, 7), the overall response rate observed in patients with NSCLC treated with sotorasib was only 32%withmedian PFS of 6.2 months.”
ResultInfluentialSelf-citationNext batter up! Targeting cancers with KRAS-G12D mutations
Zeissig, M. N., Ashwood, L. M., Kondrashova, O., & Sutherland, K. D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.010 · Cited by 128
Zhou, C., Wang, Y., Zhao, J., Chen, G., Liu, Z., Gu, K., Huang, M., He, J., Chen, J., Ma, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3136 · Cited by 138
“Furthermore, our preliminary biomarker analysis suggested that mutations in STK11 and KEAP1, which are speculated to confer resistance to (chemo-)immunotherapy as reported previously (27, 28), might dictate stronger benefit from such combination.”
BackgroundSelf-citationHorton, B. L., Morgan, D. M., Momin, N., Zagorulya, M., Torres-Mejia, E., Bhandarkar, V., Wittrup, K. D., Love, J. C., & Spranger, S. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi8800 · Cited by 133
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Mazzaschi, G., Facchinetti, F., Missale, G., Canetti, D., Madeddu, D., Zecca, A., Veneziani, M., Gelsomino, F., Goldoni, M., Buti, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.038 · Cited by 134
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
“Additionally, STK11 was identified in this study as the sole genomic alteration that is significantly enriched in PD-L1 negative tumors with an intermediate TMB profile (210).”
BackgroundInfluentialKRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 153
Self-citationOptimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 132
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 129
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 134
Self-citationKRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
“Several other trials have shown an association between KRAS mutation and improved response to ICIs[34].”
BackgroundMechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 132
“This intra-driver heterogeneity possibly explains the different responses to targeted therapy and immunotherapy of KRAS-mutated NSCLC [63].”
BackgroundLim, R. J., Salehi‐Rad, R., Tran, L. M., Oh, M. S., Dumitras, C., Crosson, W. P., Li, R., Patel, T. S., Man, S., Yean, C. E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101479 · Cited by 173
“50 In situ vaccination with CXCL9/10-DC provided broad anti-tumor efficacy in multiple murine models of lung cancer and augmented the effectiveness of anti-PD-1 therapy in murine models of LKB1-deficient NSCLC. 32–34 CXCL9/10-DC vaccination induced an initial recruitment of effector T cells, predominantly at the leading…”
InfluentialGainor, J. F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.015 · Cited by 115
Self-citationGenetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 119
Genomic landscape of pleural and peritoneal mesothelioma tumours
Hiltbrunner, S., Fleischmann, Z., Sokol, E. S., Zoche, M., Felley‐Bosco, E., & Fontecedro, A. C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01979-0 · Cited by 137
“In lung cancer, patients with STK11 mutations showed resistance to anti-PD-1 inhibitors [63], and deletions in CDKN2A were negatively correlated with T-cell markers in different cancer types [64].”
BackgroundBhatt, V., Khayati, K., Hu, Z. S., Lee, A., Kamran, W., Su, X., & Guo, J. Y. (2019) · Genes & Development · doi:10.1101/gad.320481.118 · Cited by 115
“Our findings demonstrate that autophagy could be one of the alternatives, and autophagy inhibition could particularly be effective in the treatment of LKB1-defective KRAS-driven NSCLC that failed to respond to other treatments, including immunotherapy (Siegel et al. 2015; Skoulidis et al. 2018).”
BackgroundHLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00582-9 · Cited by 113
Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.005 · Cited by 112
Self-citationNegrao, M. V., Lam, V. K., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 112
Self-citationAn LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111
“15 tumors and cell lines, we also observe lower expression of Pdl1 (Cd274) in Sik-targeted tumors (48,55).”
BackgroundSitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 111
“Previously, our group and others have reported that LKB1-deficient NSCLC are characterized by a markedly suppressed immune microenvironment within the tumor (14, 44), increased expression of T-cell exhaustion markers and tumor-promoting cytokines (19) and lack of response to PD-1/ PD-L1 inhibitors (14, 37, 45).”
BackgroundMethodSelf-citationHGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Zhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21876 · Cited by 118
“This action leads to suppression of the expression of stimulator of IFN genes (STING) in aggressive and PD‐L1 Kirsten rat sarcoma viral oncogene homolog‐mutant lung adenocarcinoma.(80,81) Emerging therapeutic strategies to restore the expressions of LKB1 or STING may promote antitumor immune response in cancers with r…”
BackgroundBest, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Tostivint, E. P., Lugat, A., Fontenau, J.-F., Denis, M. G., & Bennouna, J. (2021) · Cells · doi:10.3390/cells10113129 · Cited by 126
“Studies on cohorts of patients with NSCLC confirmed that STK11-mutant tumors could be classified as immunologically ignored, with less immune cell infiltration, as described in the following paragraph [44,45,71].”
BackgroundInfluentialCancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 126
“51 These mutations often co-occur with KRAS mutations in lung adenocarcinoma 52 and limit T cell infiltration through modulation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway.”
BackgroundThompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A. J., Kiedrowski, L. A., Lefterova, M. I., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00321 · Cited by 119
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 120
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“Skoulidis and colleagues showed that STK11/LKB1 mutation is associated with less expression of PD-L1 and decreased infiltrative CTL density, resulting in primary resistance to PD-1-based immunotherapies in both human and murine STK11/LKB1deficient lung adenocarcinoma (72).”
BackgroundMPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
Guibert, N., Jones, G., Beeler, J. F., Plagnol, V., Morris, C., Mourlanette, J., Delaunay, M., Keller, L., Rouquette, I., Favre, G., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.005 · Cited by 106
Shi, Y., Lei, Y., Liu, L., Zhang, S., Wang, W., Zhao, J., Zhao, S., Dong, X., Yao, M., Wang, K., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3649 · Cited by 121
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico, A., De Giglio, A., Parisi, C., & Gelsomino, F. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.011 · Cited by 105
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 112
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 120
“Patients without druggable oncogenes are treated with monotherapy or combination therapy with ICIs that target PD-1/PD-L1 [76, 77].”
BackgroundInfluentialSidders, B. S., Zhang, P., Goodwin, K., O’Connor, G., Russell, D. L., Borodovsky, A., Armenia, J., McEwen, R. K., Linghu, B., Bendell, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2183 · Cited by 107
Aggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K. J., Hwang, W.-T., Black, T. A., Yee, S. S., Christensen, T. E., LaRiviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102
“Clin Cancer Res; 26(10) May 15, 2020 CLINICAL CANCER RESEARCH 2356”
BackgroundInfluentialLi, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100554 · Cited by 102
“Consistent with previous reports in KL-mutated NSCLC human tumors, we found that mouse KPL tumors exhibited poor response to anti-PD-1 therapy and a T cell infiltration pattern similar to clinical STK11/LKB1mutant individuals reported previously (Figures 1A and S1F).(11) To assess the effect of Stk11/Lkb1 mutation on…”
BackgroundResultSelf-citationCombinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 115
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 105
“5c).(51) On the other hand, oncogene-driven NSCLC harboring EGFR-/BRAF−/MET-mutations or ALKrearrangements generally have lower TMB levels and responses to immunotherapy compared to wild-type tumors, despite higher PD-L1 expression.”
BackgroundNon-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 117
“Activation of β2-AR inactivates LKB1, with upregulation of CREB and interleukin-6 (IL6) [54].”
BackgroundInfluentialBiomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Sholl, L. M. (2021) · Modern Pathology · doi:10.1038/s41379-021-00932-5 · Cited by 112
Self-citationFrom Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 103
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.017 · Cited by 98
Self-citation
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.